Elevated levels of Ajuba not only stimulate breast cancer cell growth but also contribute to tamoxifen resistance, making the Ajuba/DBC1/CBP/EP300 ternary complex a new promising target for breast cancer therapy. Here, EP300 is linked to breast cancer.